2023
Systematic review and meta-analysis: Season of birth and schizophrenia risk
Coury S, Lombroso A, Avila-Quintero V, Taylor J, Flores J, Szejko N, Bloch M. Systematic review and meta-analysis: Season of birth and schizophrenia risk. Schizophrenia Research 2023, 252: 244-252. PMID: 36682315, DOI: 10.1016/j.schres.2022.12.016.Peer-Reviewed Original ResearchConceptsRisk of schizophreniaSummer birthWinter birthSystematic reviewBirth monthVitamin D deficiencyStratified subgroup analysisSchizophrenia riskEtiological risk factorsMonth of birthD deficiencySeason of birthEtiologic causesSubgroup analysisVirus exposureRisk factorsSchizophreniaMonthsBirthSignificant differencesRiskAssociation
2019
Meta-analysis: Adulthood prevalence of Tourette syndrome
Levine JLS, Szejko N, Bloch MH. Meta-analysis: Adulthood prevalence of Tourette syndrome. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2019, 95: 109675. PMID: 31220521, DOI: 10.1016/j.pnpbp.2019.109675.Peer-Reviewed Original ResearchConceptsPrevalence of TSTourette syndromeRisk ratioCases of TSPrevalence estimatesLogit event rateAccurate prevalence estimatesTS prevalenceRemission criteriaTic symptomsFemale ratioPublic health decisionsOverall prevalencePsychiatric conditionsPublication biasCase identificationEvent ratesPrevalenceHealth decisionsLongitudinal studyAdultsSignificant differencesSyndromeTS casesTwo-thirds
2018
Meta-analysis: Second generation antidepressants and headache
Telang S, Walton C, Olten B, Bloch MH. Meta-analysis: Second generation antidepressants and headache. Journal Of Affective Disorders 2018, 236: 60-68. PMID: 29715610, DOI: 10.1016/j.jad.2018.04.047.Peer-Reviewed Original ResearchConceptsRisk of headacheSecond-generation antidepressantsAntidepressant medicationGeneration antidepressantsSide effectsTreatment-emergent side effectsPlacebo-controlled trialPooled risk ratioFixed-dose trialStratified subgroup analysisTreatment of adultsDosage of medicationReceptor affinity profileSignificant differencesMeta-analysis resultsOnly antidepressantsMedication classesMedication dosingMedication typeObsessive-compulsive disorderSubgroup analysisRisk ratioRelative riskHeadacheMedications
2013
N-Acetylcysteine in the Treatment of Pediatric Trichotillomania: A Randomized, Double-Blind, Placebo-Controlled Add-On Trial
Bloch MH, Panza KE, Grant JE, Pittenger C, Leckman JF. N-Acetylcysteine in the Treatment of Pediatric Trichotillomania: A Randomized, Double-Blind, Placebo-Controlled Add-On Trial. Journal Of The American Academy Of Child & Adolescent Psychiatry 2013, 52: 231-240. PMID: 23452680, PMCID: PMC3745012, DOI: 10.1016/j.jaac.2012.12.020.Peer-Reviewed Original ResearchConceptsN-acetylcysteinePharmacological interventionsPediatric trichotillomaniaBenefit of NACBehavioral therapySecondary outcome measuresTreatment of childrenClinician-rated improvementMassachusetts General HospitalTreat populationPlacebo groupPrimary outcomeNAC groupGeneral HospitalOutcome measuresTreatment respondersSecondary measuresPlaceboTreatment assignmentTrichotillomaniaLinear mixed modelsTrialsSignificant differencesChildrenTherapySymptom dimensions are associated with age of onset and clinical course of obsessive–compulsive disorder
Kichuk SA, Torres AR, Fontenelle LF, Rosário MC, Shavitt RG, Miguel EC, Pittenger C, Bloch MH. Symptom dimensions are associated with age of onset and clinical course of obsessive–compulsive disorder. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2013, 44: 233-239. PMID: 23410525, PMCID: PMC3654083, DOI: 10.1016/j.pnpbp.2013.02.003.Peer-Reviewed Original ResearchConceptsAge of onsetClinical courseObsessive-compulsive disorderPrimary symptom dimensionsSymptom dimensionsPrimary OCD symptomsChi-square testEarly ageOCD symptom dimensionsYale-Brown ObsessiveAdult patientsComorbid ticsSignificant symptomsLarge cohortDifferent OCD symptom dimensionsHeterogeneous symptomsSymptomsCompulsive ScaleDimensional Yale-Brown ObsessiveAgeSignificant differencesOCD symptomsOnsetInconsistent results